新型Amplatzer封堵器治疗膜周部室间隔缺损的临床研究

目的探讨新型Amplatzer室间隔缺损封堵器治疗膜周部室间隔缺损(PMVSD)的临床疗效。方法采用新型Amplatzer膜周部室间隔缺损封堵器,对46例PMVSD患者进行封堵治疗。对心脏多普勒超声检查符合导管封堵条件的患者术前常规进行心导管检查,测定血流动力学参数。在X线透视、食管超声心动图(TEE)的监测下建立股动静脉轨道,经右心系统释放封堵器。病人分别于术后24小时、1个月、3个月、6个月进行随访。结果46例患者中除2例因室间隔缺损膜部瘤松软未能成功置入外,其余患者均能正确置放新型Amplatzer封堵器和即刻完全封堵PM-VSD。术后24小时至6个月进行TEE复查,所有患者被完全封堵。结论新型Amplatzer封堵器治疗PMVSD是一种安全、成功率高、近期疗效可靠的介入方法。     

应用Amplatzer封堵器治疗膜周部室间隔缺损

1.资料与方法:(1)病例资料:2003年3月至2005年5月,经胸超声心动图检查确诊的膜周部室间隔缺损(VSD)患者68例,年龄14.0～51.0岁,平均(21.6±10.7)岁。其中膜周靠近隔瓣(膜周流入部)32例,30例合并膜部瘤;膜周靠近肺动脉瓣(膜周流出部)13例,膜部靠近室上嵴23例;经胸超声测量缺损直径3.3～14.0MM,平均(4.7±1.1)MM,心电图均为窦性心律。(2)方法:按《先天性心脏病导管介入治疗指南》封堵VSD,术后处理及随访。术中采用经胸超声监测,计量资料采用SPSS12.0软件包进行处理。2.结果:68例VSD左室造影显示有32例合并膜部瘤占44%,为膜周流入部型,…     

国产膜周部室间隔缺损封堵器的研制及临床应用

目的 评价我们研制的一种国产膜周部室间隔缺损(VSD)封堵器的临床应用价值及安全性。方法膜周部VSD封堵器的结构设计为“工”字形,有对称型及非对称型两种,金属材料选用镍钛形状记忆合金,阻流体选用聚四氟乙烯。通过动物实验及临床试验,对该装置的安全性、有效性和并发症进行评价,并与Amplatzer封堵器进行对比,对该装置进行综合评价。结果封堵器检验合格并通过国家安全检测。成功建立VSD模型的22头猪均成功置入封堵器,随诊除1例伤口感染外无并发症发生。进行临床实验的58例膜周部VSD病例全部成功置入封堵器,1例出现Ⅱ度Ⅱ型房室传导阻滞,其余无并发症发生。新型膜周部VSD封堵器与Amplatzer封堵器相比成功率、并发症方面差异无统计学意义。但术后即刻封堵效果优于Amplatzer封堵器。结论我们研制的封堵器结构设计合理,是一种疗效确切的膜周部VSD介入治疗装置,达到或优于进口Amplatzer装置的治疗效果。     

经导管应用Amplatzer封堵器关闭膜周部室间隔缺损

目的 :经导管应用Amplatzer封堵器关闭膜周部室间隔缺损 (perimembranousventricularseptaldefect,PMVSD) ,并对其疗效进行初步分析。方法 :18例室间隔缺损 (VSD)中男性 8例 ,女性 10例 ,平均年龄 7 6岁 ,平均体重 2 6 9kg。局麻下行右心导管检查 ,左室造影测量室缺大小 ,经VSD建立股动脉 股静脉轨道 ,封堵器沿传送装置送至左室 ,打开左侧伞并确认铂金标记 (MARK)位于 6点位 ,指向心尖 ,在室间隔右室侧打开右侧伞 ,经超声心动图和左室造影确认封堵器位置良好 ,无残余分流 ,无三尖瓣及主动脉瓣关闭不全后释放封堵器。结果 :18例VSD患者封堵手术均获成功。VSD平均大小 3 9mm ,所选封堵器平均大小 7 1mm ,放射线观察MARK均在 6点位置。封堵效果良好 ,术后 2 4h左室舒张末径明显缩小 ;术后 2 4h仅 2例有微量残余分流 ,无 1例出现主动脉瓣关闭不全 ,无其它严重并发症 ,平均住院3 5d。结论 :经导管应用Amplatzer封堵器关闭膜周部VSD封堵效果好 ,恢复快 ,免除开胸创伤及体外循环等高风险 ,值得进一步推广。     

膜周部室间隔缺损介入治疗的临床评价

目的:评价膜周部室间隔缺损(VSD)经导管封堵治疗的临床效果。 方法:456例患者,经胸超声心动图测量VSD直径为3-18(6.2±3.1)mm,VSD距主动脉右冠瓣距离0.5-5.0(2.3±1.0)mm。其中6例合并动脉导管未闭,7例合并房间隔缺损,1例合并动脉导管未闭和房间隔缺损。19例伴轻度主动脉右冠瓣脱垂。先行左心室造影,通过VSD建立动静脉轨道,应用7-10F输送鞘管从右心系统送入封堵器。 结果:左心室造影测量VSD直径为3-20(6.4±3.0)mm,VSD距主动脉右冠瓣距离0.5-6.0(2.4±1.1)mm,其中86例患者VSD距主动脉右冠瓣距离<2 mm。391例伴膜部瘤形成。448例患者封堵成功,成功率为98％。未成功的8例中,2例导管未能通过缺损处,2例术中导丝通过VSD出现Ⅲ度房室传导阻滞(AVB),2例封堵后出现间歇性Ⅲ度AVB,2例伴主动脉右冠瓣轻度脱垂患者封堵后有少-中量主动脉瓣反流而放弃封堵治疗。所选封堵器大小为4-22(8.6±3.1)mm。封堵器到位后即刻左心室造影示微量残余分流68例,6个月复查超声心动图有1例微量残余分流。术后发生高度AVB 6例,1例安装永久起搏器。封堵器向膜部瘤出口明显移位1例,外科取出封堵器并行手术修补VSD。溶血2例,三尖瓣中量反流1例。合并动脉导管未闭6例、房间隔缺损7例、合并动脉导管未闭和房问隔缺损1例,同时成功封堵。 结     

国产封堵器治疗膜周部室间隔缺损并发膜部瘤的临床研究

膜周部室间隔缺损(ventricular septal defect，VSD)是先天性VSD最常见的类型，其介入治疗一直是人们探索的领域。自2002年Amplatzer膜周部VSD封堵器和国产膜周部VSD封堵器被临床应用以来，国内已完成2000余病例。但对于VSD并发膜部瘤的介入治疗报道较少。我院自2004年10月～12月用国产封堵器治疗膜周部VSD并发膜部瘤患者58例，取得了良好效果。     

应用Amplatzer偏心性封堵器介入治疗膜部室间隔缺损

目的　应用Amplatzer偏心性封堵器治疗膜部室间隔缺损 (perimembraneventicularseptaldefect,PMVSD)并对近期疗效进行观察。方法　 6例PMVSD患者均经胸超声心动图确诊 ,术中经左心室造影明确缺损直径为 3～ 9mm ,平均 5 5mm ;经左心系统、室间隔缺损处、右心系统建立导丝轨迹 ,沿导丝经传送鞘管送直径 6～ 12mm(平均 8mm)的Amplatzer封堵器至缺损处行封堵 ;术后 2 4h、1月、3月分别行经胸超声及X线检查观察临床疗效。结果　全组技术成功率 10 0 % ,术中未发生任何重要并发症。全部患者封堵后无一例存在残余分流 ,术后即刻完全封堵率 10 0 % ;术后 2 4h、1月及 3月经胸超声心动图检查无残余分流 ,X线检查全部显示肺血减少 ,心胸比例不同程度缩小。 1例患者术后出现完全性左束支传导阻滞 ,1月随访时消失。结论　经导管置入Amplatzer偏心性膜部室间隔缺损封堵器治疗PMVSD是一种成功率高、近期疗效可靠的介入方法 ,其远期疗效需进一步观察。     

国产室间隔封堵器治疗膜部室间隔缺损的应用

目的：探讨国产室间隔封堵器治疗膜部室间隔缺损的效果。方法：回顾性总结3例膜部室隔缺损（VSD）用国产室间隔封堵器治疗的资料。结果：2例成功封堵VSD，1例封堵器到位后严重变形，无法封堵，转外科手术。结论：国产室间隔封堵器有实用价值，但质量不完全可靠。     

国产封堵器经导管介入治疗膜周部室间隔缺损379例

膜周部室间隔缺损(PMVSD)是常见的先天性心脏病之一,我们应用国产封堵器经导管介入治疗PMVSD,已成功完成病例364例,临床结果较为满意.     

应用新型Amplatzer封堵器治疗膜周部室间隔缺损的初步研究

目的　探讨新型Amplatzer室间隔缺损封堵器治疗膜周部室间隔缺损 (VSD)的可行性及近期疗效。方法　 2 0 0 2年 11月至 2 0 0 3年 7月采用新型Amplatzer膜部VSD封堵器对 2 6例 (男 11例 ,女 15例 )膜周部VSD(2 0例合并膜部瘤 )患者进行封堵治疗。患者年龄 3～ 4 0 (16 4± 10 7)岁 ,胸超声提示VSD的直径为 3～ 14 (4 7± 1 0 )mm。在透视及超声监测下通过建立股动静脉轨道、经右心系统释放封堵器 ,并分别于术后 2周、1个月、3个月、6个月进行随访。结果　 2 5例患者封堵器置入成功 ,技术成功率 96 %。术后即刻超声及造影均示完全封堵 2 0例 ,少量残余分流 2例 ,微量残余分流 3例 ,均在 1天至 3个月内消失 ,总完全封堵率为 10 0 %。术后出现完全性左束支传导阻滞 1例 ,但无心肌受损表现 ,余无其他严重并发症发生。 1例嵴内型VSD由于距主动脉瓣较近 ,封堵未成功。结论　应用新型Amplatzer膜部VSD封堵器治疗膜周部VSD是安全有效的 ,近期效果良好 ,但中、远期疗效尚需更大规模的临床观察     

Percutaneous transcatheter ventricular septal defect closure in adults with Amplatzer septal occluders

BACKGROUND: The interest in transcatheter ventricular septal defect (VSD) closure is continuously growing. Therefore, we report our experience in perimembranous (Pm) and postinfarction (Pi) VSD closure. METHODS: All patients, older than 16 years, were selected from a data base, in which Pm and Pi VSDs were registered.The patients' files were reviewed until the most recent follow-up date. RESULTS: Nine (7 male, 37.4 +/- 12.8 y) and 8 (6 male, 76.3 +/- 6.2 y) patients underwent a Pm (group A) and Pi VSD (group B) closure, respectively. One female patient was treated for a posttraumatic VSD (26 y). In group A, 7 patients were closed with the Amplatzer perimembranous VSD occluder, one with the muscular VSD occluder, and one patient with the atrial septal defect occluder. All patients in group B were treated with the muscular VSD occluder. In the post-traumatic VSD an Amplatzer patent foramen ovale occluder was used. Device implantation was feasible in all, except in two patients with extremely large VSDs (one Pm and one PiVSD). Total transcatheter closure or small residual leakage was achieved in 7/8 patients in group A, but one patient needed surgical VSD repair because of massive haemolysis, another patient died 9 months later. A small or moderate shunt was present immediately after the procedure in all patients of group B. No device-related complications were reported, but all, except one patient, died within 2 weeks after the procedure because of an extremely high co-morbidity (logistic Euroscore 70 +/- 25%).Total closure was achieved in the post-traumatic VSD. CONCLUSION: Transcatheter closure of Pm and Pi VSD with Amplatzer septal occluders in adults is feasible and safe, but the post-procedural prognosis totally depends on the aetiology of the VSD and its co-morbidity.     

Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders

OBJECTIVES: The aim of this study was to assess long-term results of percutaneous closure of secundum-type atrial septal defect (ASD II) using Amplatzer septal occluders (ASO). BACKGROUND: Only immediate-, short-, and intermediate-term results of ASO implantation are known so far. METHODS: Between September 1995 and January 2000, 151 patients underwent a successful percutaneous closure of ASD II in our institution. All were included in the present study and were followed up until September 2004. RESULTS: This group of patients was followed up from 56 to 108 months (median 78 months). The mean stretched defect diameter was 15.9 +/- 4.8 mm. There were no deaths or significant complications during the study. At three years of follow-up, all defects were completely closed and remained closed thereafter. CONCLUSIONS: Since the first human implantations in September 1995, the Amplatzer septal occluder proved as a safe and effective device for percutaneous closure of ASD II.     

介入治疗膜周部室间隔缺损后早期的心律失常

目的探讨介入治疗膜周部室间隔缺损后早期心律失常的特点。方法回顾性分析膜周部室间隔缺损273例心电图资料，了解介入封堵术后早期发生的各种类型心律失常。分析封堵器类型、缺损大小及有无膜部瘤对心律失常发生的影响。结果心律失常发生率33．0％（90／273），其中传导阻滞占68．9％（62／90）。国产和进口封堵器组的心律失常差异无统计学意义（P〉0．05）；室间隔缺损小于5mm组和不小于5mm组的心律失常发生率分别为25．8％、49．4％（P〈0．05）。结论膜周部室间隔缺损介入治疗后早期心律失常发生率较高，以传导阻滞为主。室间隔缺损大小和有无膜部瘤是影响术后早期心律失常的重要因素。     

Novel transcatheter closure of an iatrogenic perimembranous ventricular septal defect

Iatrogenic membranous ventricular septal defects (VSD) are rare complications of cardiothoracic surgery, most commonly seen as a complication of aortic valve replacements. An iatrogenic VSD can lead to right sided heart failure, systemic hypoxia, and arrhythmias, and closure is often necessary. Given the increased mortality associated with repeat surgical procedures, percutaneous transcatheter closure of these iatrogenic VSDs has increasingly become the preferred choice of therapy. We describe the first case of iatrogenic membranous VSD in the setting of mitral valve replacement and tricuspid valve repair, using the newly approved Amplatzer Duct Occluder II Device from an entirely retrograde approach. © 2014 Wiley Periodicals, Inc.     

介入治疗膜周部室间隔缺损后早期的心律失常

目的探讨介入治疗膜周部室间隔缺损后早期心律失常的特点。方法回顾性分析膜周部室间隔缺损273例心电图资料，了解介入封堵术后早期发生的各种类型心律失常。分析封堵器类型、缺损大小及有无膜部瘤对心律失常发生的影响。结果心律失常发生率33．0％（90／273），其中传导阻滞占68．9％（62／90）。国产和进口封堵器组的心律失常差异无统计学意义（P〉0．05）；室间隔缺损小于5mm组和不小于5mm组的心律失常发生率分别为25．8％、49．4％（P〈0．05）。结论膜周部室间隔缺损介入治疗后早期心律失常发生率较高，以传导阻滞为主。室间隔缺损大小和有无膜部瘤是影响术后早期心律失常的重要因素。     

Transcatheter closure of perimembranous ventricular septal defects in infants and children using the Amplatzer perimembranous ventricular septal defect occluder

There are very few published reports of the transcatheter closure of perimembranous ventricular septal defects (PMVSDs) using the Amplatzer PMVSD occluder with encouraging initial results. This report presents initial and 1-year results from 54 patients with PMVSDs who underwent transcatheter closure at 5 different institutions with the Amplatzer PMVSD occluder. Sixty-five patients with PMVSDs were enrolled at 5 European centers. Eleven of the 65 patients did not fulfill the patient selection criteria at the initial echocardiographic evaluation or at cardiac catheterization. As a result, a total of 54 patients underwent attempted transcatheter closure using the Amplatzer PMVSD occluder. The median age of the patients was 5.1+/-3.6 years (range 0.3 to 13), and the median weight 18.5+/-10.3 kg (range 5 to 45). Devices were permanently implanted in 49 of 54 patients. Complete occlusion of the communication at 1-year follow-up was observed in 46 of 49 patients (94%). Main early procedural complications included (1) device embolization (2 patients), (2) severe bradycardia with hemodynamic compromise (2 patients), and (3) Mobitz II (2:1) heart block (1 patient). Late procedural complications included complete heart block (1 patient). No other complications were observed during follow-up. In conclusion, the Amplatzer PMVSD occluder is promising device that can be used for transcatheter closure in selected patients with PMVSDs. Further studies and long-term follow-up are required before this technique enters routine clinical practice.     

国产动脉导管封堵器闭合膜周部室间隔缺损的疗效评价

目的评价国产动脉导管（PDA）封堵器闭合膜周部室间隔缺损（VSD）的可行性、安全性及疗效。方法2004年5月至2008年7月,21例先天性膜周部VSD患者[男性10例,女性11例,年龄5～40（21．3±10．2）岁]成功接受了封堵治疗。膜周部VSD的直径均先经经胸心脏彩超检查（TTE）测量,并经左心室造影进一步明确。封堵操作完成10min后再次予TTE及左心室造影评估封堵效果。术后心电监护1周,出院前及出院后1、3、6个月随访复查TTE及心电图。结果21例患者均全部封堵成功,国产PDA封堵器尺寸为6／8～18／20mm。封堵后,2例新出现微量主动脉瓣反流,1例出现少量的三尖瓣反流;3例出现完全性或不完全性右束支传导阻滞,1例出现完全性左束支传导阻滞,1例出现不完全右束支合并间歇性完全性左束支传导阻滞,除2例完全性或不完全性右束支传导阻滞在6个月内随访时未恢复外,其他3例均在出院前恢复正常;4例存在微量残余分流,其中3例在7d后复查超声时消失,另1例在1个月随访时消失。术前TTE估测肺动脉压力为28．0～46．7（33．4±9．2）mmHg,术后肺动脉压力为16．0-30．2（19．2±7．6）mmHg,6个月随访时肺动脉压力进一步下降为15．3-26．7（17．3±6．9）mmHg。结论对部分膜周部室间隔缺损的患者应用PDA封堵器进行封堵是可行的、安全的及有效的。     

Transcatheter closure of perimembranous ventricular septal defect using an Amplatzer occluder--early results

BACKGROUND: Transcatheter closure of perimembranous ventricular septal defect with the use of an Amplatzer occluder was introduced in 1999, however, clinical experience with this method remains limited. AIM: To assess short-term safety and efficacy of this technique in children. METHODS: Since 2001, nine children underwent transcatheter closure of perimembranous ventricular septal defect in the cardiac centre in Bratislava (Slovak Republic) or in our centre. Patients were selected for the procedure based on the results of transesophageal echocardiography (TEE). Transcatheter closure using the Amplatzer occluder was guided by both TEE and angiography. The follow-up duration ranged from 3 to 22 months, mean 11.5 months. Control angiography was performed in order to detect any leakage through the aortic valve. The end-diastolic left ventricular diameter before and after the procedure as well as the function of the aortic, tricuspid and mitral valves were also assessed. RESULTS: The procedure was effective in all patients. No damage to atrio-ventricular nor aortic valves was observed. Tricuspid regurgitation, present prior to the procedure, markedly decreased following the closure of the defect. The left ventricular end-diastolic diameter significantly (p=0.001) decreased after the procedure. CONCLUSIONS: (1) Perimembranous ventricular septal defect can be safely and effectively closed using a transcatheter Amplatzer occluder. (2) Appropriate selection for the procedure as well as TEE and angiographic guidance during the procedure enable the avoidance of complications. (3) Tricuspid regurgitation is not an absolute contraindication to perform this procedure.